(Q40246078)

18 September 2017

Safety profile of antiviral medications: a pharmacovigilance study using the Italian spontaneous-reporting database (English)

1 reference

18 September 2017

0 references

Carlo Piccinni

9

0 references

Domenico Motola

object named as

Domenico Motola

8

0 references

Alfredo Vannacci

object named as

Alfredo Vannacci

13

0 references

Marco Rossi

object named as

Marco Rossi

7

0 references

author name string

Alessandra Pugi

1

1 reference

18 September 2017

Roberto Bonaiuti

2

1 reference

18 September 2017

Valentina Maggini

3

1 reference

18 September 2017

Martina Moschini

4

1 reference

18 September 2017

Marco Tuccori

5

1 reference

18 September 2017

Roberto Leone

6

1 reference

18 September 2017

Fernanda Ferrazin

10

1 reference

18 September 2017

Laura Sottosanti

11

1 reference

18 September 2017

Alessandro Mugelli

12

1 reference

18 September 2017

Francesco Lapi

14

1 reference

18 September 2017

1 June 2013

1 reference

American Journal of Health-System Pharmacy

18 September 2017

1 reference

18 September 2017

70

1 reference

18 September 2017

12

1 reference

18 September 2017

1039-1046

1 reference

Antiviral drugs for viruses other than human immunodeficiency virus

18 September 2017

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Side effects of therapy for chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Understanding and managing the adverse effects of antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Side effects of long-term oral antiviral therapy for hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

A Systematic Review of Side Effects of Nucleoside and Nucleotide Drugs Used for Treatment of Chronic Hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Renal Disease Associated with Antiretroviral Therapy in the Treatment of HIV

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Hematologic disorders associated with hepatitis C virus infection and their management

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

HIV/HCV co-infection: pathogenesis, clinical complications, treatment, and new therapeutic technologies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Hepatitis B: the virus and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Predictors of hematological abnormalities in patients with chronic hepatitis C treated with interferon and ribavirin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Viral hepatitis and HIV coinfection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Nucleoside analogues and mitochondrial toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

An Italian approach to postmarketing monitoring: preliminary results from the SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals) project on the safety of lopinavir/ritonavir

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Adverse drug reactions to antiretroviral therapy (ART): an experience of spontaneous reporting and intensive monitoring from ART centre in India

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

A method for estimating the probability of adverse drug reactions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Hepatic adverse drug reactions: a case/non-case study in Italy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Statin-associated psychiatric adverse events: a case/non-case evaluation of an Italian database of spontaneous adverse drug reaction reporting

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Allergic reactions to oral drugs: A case/non-case study from an Italian spontaneous reporting database (GIF).

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

The impact of confounder selection criteria on effect estimation

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Drug-induced taste and smell alterations: a case/non-case evaluation of an italian database of spontaneous adverse drug reaction reporting.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Hematologic side effects of interferon and ribavirin therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Hyperthyroidism with interferon-ribavirin therapy for hepatitis C: a case report and proposed treatment algorithm.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Interferon induced thyroiditis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

The natural history of interferon-alpha2b-induced thyroiditis and its exclusivity in a cohort of patients with chronic hepatitis C infection

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Hepatitis C, interferon alfa, and depression

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Changes in mood states and biomarkers during peginterferon and ribavirin treatment of chronic hepatitis C.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Incidence and risk factors for the development of indinavir-associated renal complications

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Acyclovir-induced neurotoxicity: concentration-side effect relationship in acyclovir overdose

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Valacyclovir neurotoxicity: clinical experience and review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Aciclovir neurotoxicity is an important side effect of therapy in patients with renal impairment.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Neurological toxicity of acyclovir: report of a case in a six-month-old liver transplant recipient

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Acute renal failure and severe neurotoxicity following valacyclovir.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Acute renal failure induced by intravenous acyclovir

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Severe acute renal failure in an HIV-infected patient after only 2 weeks of tenofovir-based antiretroviral therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

The quality of published adverse drug event reports

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Causal or casual? The role of causality assessment in pharmacovigilance.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Physician's guide to pharmacovigilance: terminology and causality assessment

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: the notoriety bias

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Biases affecting the proportional reporting ratio (PPR) in spontaneous reports pharmacovigilance databases: the example of sertindole

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

Harmonisation in pharmacovigilance

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP120665

31 March 2020

Identifiers

DOI

10.2146/AJHP120665

1 reference

18 September 2017

1 reference